Crohn

AbbVie has received approval from the US Food and Drug Administration (FDA) for its Humira (adalimumab) to treat paediatric patients with moderately to severely active Crohn’s disease.

The drug has been developed to reduce signs and symptoms, as well as to achieve and maintain clinical remission in paediatric Crohn’s disease patients six years of age and older.

The approval represents the eighth indication for Humira in the US, and is the only biologic approved to treat patient population that can be administered at home.

"Children living with moderate to severe Crohn’s disease have limited treatment options and AbbVie is pleased that Humira will now be an available option for many of these patients."

AbbVie chief scientific officer and research and development executive vice-president Michael Severino said: "Children living with moderate to severe Crohn’s disease have limited treatment options and AbbVie is pleased that Humira will now be an available option for many of these patients.

"This approval underscores our continued commitment to innovate with Humira, both in studying potential new indications to help meet unmet medical needs and in helping to improve the standard of care for patients living with immune-mediated inflammatory diseases like Crohn’s disease."

See Also:

The approval was based on the Phase III IMAgINE-1 trial, which assessed multiple dosing strategies of Humira to induce and maintain clinical remission in paediatric patients with moderately to severely active Crohn’s disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In 2012, the European Commission granted approval for Humira to treat paediatric patients with aged six to 17 years with severe active Crohn’s disease.

Crohn’s disease is a type of inflammatory bowel disease (IBD), which involves the end of the small intestine and the large intestine.

Image: High magnification micrograph of Crohn’s disease. Biopsy of colon. H&E stain. Photo: courtesy of Nephron.